Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Nikolett Pahor"'
Autor:
Cristian Prieto‐Garcia, Oliver Hartmann, Michaela Reissland, Fabian Braun, Süleyman Bozkurt, Nikolett Pahor, Carmina Fuss, Andreas Schirbel, Christina Schülein‐Völk, Alexander Buchberger, Marco A. Calzado Canale, Mathias Rosenfeldt, Ivan Dikic, Christian Münch, Markus E. Diefenbacher
Publikováno v:
Molecular Oncology, Vol 16, Iss 17, Pp 3082-3106 (2022)
Oncogenic transformation of lung epithelial cells is a multistep process, frequently starting with the inactivation of tumour suppressors and subsequent development of activating mutations in proto‐oncogenes, such as members of the PI3K or MAPK fam
Externí odkaz:
https://doaj.org/article/dce85c56cd0547f996b0cfb97c5fb3dc
Autor:
Thomas Fischer, Oliver Hartmann, Michaela Reissland, Cristian Prieto-Garcia, Kevin Klann, Nikolett Pahor, Christina Schülein-Völk, Apoorva Baluapuri, Bülent Polat, Arya Abazari, Elena Gerhard-Hartmann, Hans-Georg Kopp, Frank Essmann, Mathias Rosenfeldt, Christian Münch, Michael Flentje, Markus E. Diefenbacher
Publikováno v:
Cell & Bioscience, Vol 12, Iss 1, Pp 1-22 (2022)
Abstract Background Despite advances in treatment of patients with non-small cell lung cancer, carriers of certain genetic alterations are prone to failure. One such factor frequently mutated, is the tumor suppressor PTEN. These tumors are supposed t
Externí odkaz:
https://doaj.org/article/6e2b77747e884b2d9b01fa05018ce46e
Autor:
Oliver Hartmann, Michaela Reissland, Carina R. Maier, Thomas Fischer, Cristian Prieto-Garcia, Apoorva Baluapuri, Jessica Schwarz, Werner Schmitz, Martin Garrido-Rodriguez, Nikolett Pahor, Clare C. Davies, Florian Bassermann, Amir Orian, Elmar Wolf, Almut Schulze, Marco A. Calzado, Mathias T. Rosenfeldt, Markus E. Diefenbacher
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 9 (2021)
Lung cancer is the most common cancer worldwide and the leading cause of cancer-related deaths in both men and women. Despite the development of novel therapeutic interventions, the 5-year survival rate for non-small cell lung cancer (NSCLC) patients
Externí odkaz:
https://doaj.org/article/25bb6c9a9e3b4539a37791d85b52657e
Autor:
Marnet Victoria Louise, Oliver Hartmann, Michaela Reissland, Nikolett Pahor, Laura-Sophie Landwehr, Martin Fassnacht, Fuss Carmina Teresa, Diefenbacher Markus Elmar
Publikováno v:
Endocrine Abstracts.
Autor:
Michaela Reissland, Oliver Hartmann, Saskia Tauch, Cristian Prieto-Garcia, Clemens Schulte, Daniel Solvie, Sinah Loebbert, Anne-Claire Jacomin, Marina Pesic, Jeroen Bugter, Christina Schülein-Völk, Carmina Fuss, Nikolett Pahor, Carsten Ade, Viktoria Buck, Michael Potente, Vivian Li, Gerti Beliu, Armin Wiegering, Eliya Bitman-Lotan, Tom Grossmann, Mathias Rosenfeldt, Martin Eilers, Hans Maric, Madelon Maurice, Florian Greten, Ivan Dikic, Amir Oryan, Peter Gallant, Markus Diefenbacher
The contribution of deubiquitylating enzymes to β-Catenin stabilisation in intestinal stem cells and colorectal cancer (CRC) is poorly understood. Here, we report the deubiquitylase USP10 as an APC-truncation- specific enhancer of β-Catenin stabili
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7cbc08d25e5786a9e89293d3727f74c9
https://doi.org/10.21203/rs.3.rs-2647009/v1
https://doi.org/10.21203/rs.3.rs-2647009/v1
Autor:
Fuss Carmina Teresa, Oliver Hartmann, Michaela Reissland, Nikolett Pahor, Laura-Sophie Landwehr, Martin Fassnacht, Markus E Diefenbacherc
Publikováno v:
Endocrine Abstracts.
Autor:
Oliver, Hartmann, Michaela, Reissland, Carina R, Maier, Thomas, Fischer, Cristian, Prieto-Garcia, Apoorva, Baluapuri, Jessica, Schwarz, Werner, Schmitz, Martin, Garrido-Rodriguez, Nikolett, Pahor, Clare C, Davies, Florian, Bassermann, Amir, Orian, Elmar, Wolf, Almut, Schulze, Marco A, Calzado, Mathias T, Rosenfeldt, Markus E, Diefenbacher
Publikováno v:
Frontiers in Cell and Developmental Biology
Lung cancer is the most common cancer worldwide and the leading cause of cancer-related deaths in both men and women. Despite the development of novel therapeutic interventions, the 5-year survival rate for non-small cell lung cancer (NSCLC) patients